GR2302

N/A

Report date: 2026/03/19 17:03:51
NME

Base Information

Drug NameGR2302
Drug Alias NameGR-2302
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-HBsAg
TargetsT cell surface glycoprotein CD3Hepatitis B Surface Antigens
Therapy Area/IndicationsLiver NeoplasmsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChongqing Genrix Biopharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChongqing Genrix Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver NeoplasmsHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A